Affinity Asset Advisors LLC Invests $2.26 Million in Monopar Therapeutics Inc. $MNPR

Key Points

• Affinity Asset Advisors LLC acquired 62,000 shares of Monopar Therapeutics, representing approximately $2.26 million, which gives them a 1.01% stake in the company.
• Recent insider sales included transactions by Director Christopher M. Starr and CEO Chandler Robinson, both selling 16,800 shares at $40.00 each, significantly reducing their ownership in the company.
• Brokerage firms have set aggressive price targets for Monopar Therapeutics, with estimates ranging from $60.00 to $74.00, indicating strong buy recommendations from multiple analysts.

Affinity Asset Advisors LLC purchased a new stake in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 62,000 shares of the company's stock, valued at approximately $2,257,000. Affinity Asset Advisors LLC owned about 1.01% of Monopar Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. AlphaQuest LLC bought a new stake in Monopar Therapeutics during the first quarter valued at $44,000. JPMorgan Chase & Co. bought a new position in shares of Monopar Therapeutics during the 4th quarter worth about $45,000. Gerber LLC bought a new position in shares of Monopar Therapeutics during the 1st quarter worth about $204,000. Geode Capital Management LLC boosted its position in shares of Monopar Therapeutics by 174.4% during the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock worth $849,000 after purchasing an additional 24,530 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new position in shares of Monopar Therapeutics during the 4th quarter worth about $3,694,000. Institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Trading Down 5.3%

Shares of MNPR traded down $1.91 on Friday, reaching $34.15. The company's stock had a trading volume of 15,130 shares, compared to its average volume of 34,835. Monopar Therapeutics Inc. has a twelve month low of $2.25 and a twelve month high of $54.30. The stock has a market capitalization of $210.71 million, a PE ratio of -10.26 and a beta of 1.05. The firm has a fifty day moving average of $37.89 and a 200-day moving average of $36.82.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.12. As a group, equities analysts anticipate that Monopar Therapeutics Inc. will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, CEO Chandler Robinson sold 16,800 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the sale, the chief executive officer owned 73,472 shares in the company, valued at approximately $2,938,880. This trade represents a 18.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christopher M. Starr sold 16,800 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the sale, the director owned 5,173 shares of the company's stock, valued at approximately $206,920. The trade was a 76.46% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,504 shares of company stock worth $1,700,160. Insiders own 20.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. HC Wainwright assumed coverage on shares of Monopar Therapeutics in a research report on Tuesday, August 26th. They set a "buy" rating and a $70.00 price objective on the stock. Chardan Capital reissued a "buy" rating and set a $60.00 price objective on shares of Monopar Therapeutics in a research report on Wednesday, August 13th. Cantor Fitzgerald reissued an "overweight" rating and set a $74.00 price objective on shares of Monopar Therapeutics in a research report on Wednesday. Finally, Wall Street Zen raised shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $66.00.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.